TEMPI syndrome

=TEMPI Syndrome = TEMPI syndrome is a rare and recently identified disorder characterized by a constellation of clinical features. The acronym TEMPI stands for Telangiectasias, Erythrocytosis with elevated erythropoietin levels, Monoclonal gammopathy, Perinephric fluid collections, and Intrapulmonary shunting.

Clinical Features

Telangiectasias

Telangiectasias are small, dilated blood vessels near the surface of the skin or mucous membranes. In TEMPI syndrome, these are often visible on the skin and can be a diagnostic clue.

Erythrocytosis

Erythrocytosis refers to an increased number of red blood cells in the bloodstream, which can lead to increased blood viscosity and associated complications. In TEMPI syndrome, this is accompanied by elevated levels of erythropoietin, a hormone that stimulates red blood cell production.

Monoclonal Gammopathy

Monoclonal gammopathy is the presence of an abnormal protein in the blood produced by a clone of plasma cells. This is a common feature in TEMPI syndrome and can be detected through serum protein electrophoresis.

Perinephric Fluid Collections

Perinephric fluid collections are accumulations of fluid around the kidneys. These can be identified through imaging studies such as ultrasound or CT scans.

Intrapulmonary Shunting

Intrapulmonary shunting refers to the passage of blood from the right side to the left side of the heart without being oxygenated in the lungs. This can lead to hypoxemia and is a significant feature of TEMPI syndrome.

Diagnosis

The diagnosis of TEMPI syndrome is based on the identification of its characteristic clinical features. A thorough clinical evaluation, laboratory tests, and imaging studies are essential for diagnosis. The presence of a monoclonal gammopathy, elevated erythropoietin levels, and the other features mentioned above are key diagnostic criteria.

Treatment

Treatment of TEMPI syndrome is challenging due to its rarity and the complexity of its symptoms. Management often involves addressing each of the individual components of the syndrome. For example, erythrocytosis may be managed with phlebotomy or medications to reduce red blood cell production. Monoclonal gammopathy may require treatment with medications such as corticosteroids or immunomodulatory drugs.

Prognosis

The prognosis of TEMPI syndrome varies depending on the severity of the symptoms and the response to treatment. Early diagnosis and management of the individual components of the syndrome can improve outcomes.

Research

Ongoing research is focused on understanding the underlying pathophysiology of TEMPI syndrome and developing targeted therapies. Due to its rarity, collaboration among researchers and clinicians is essential to advance knowledge and treatment options.

See Also

• Rare diseases
• Monoclonal gammopathy of undetermined significance
• Polycythemia

External Links

• National Institutes of Health - TEMPI Syndrome

NIH genetic and rare disease info

• NIH info on TEMPI syndrome

TEMPI syndrome is a rare disease.